Innate hopes dosing tweak will save BMS-partnered lirilumab

BMS licensed lirilumab in a $465 million deal in 2011.

Innate Pharma has admitted that it can’t see an obvious way to bring its cancer antibody lirilumab forward in development after it flunked a second clinical trial.

The French biotech has revealed the combination of lirilumab and Bristol-Myers Squibb’s PD-1 inhibitor Opdivo (nivolumab) failed to show any additional benefit compared to Opdivo alone in patients with squamous cell carcinoma of the head and neck (SCCHN) ahead of the Thanksgiving break, sending its shares into steep decline.

That disappointment comes in the wake of a failed phase 2 trial in which the anti-killer cell immunoglobulin-like receptor (KIR) antibody was unable to improve progression-free survival (PFS) compared to placebo in elderly patients with acute myeloid leukemia (AML).

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

A trio of disappointing trials put the future of the drug—partnered with BMS in an up-to-$465 million deal inked in 2011—firmly in doubt, although Innate isn’t ready to call time on the program just yet, saying it is still in negotiations with its partner.

It thinks there may be a lifeline for lirilumab in a new analysis of the AML trial data which suggests alternative dosing regimens in which the drug is delivered on an intermittent rather than continuous basis could improve efficacy. In essence.

Targeting KIRs, found on natural killer cells, is intended to rev up the ability of the immune system to seek out and destroy malignant cells. Innate’s latest idea is that continual blockade of KIR isn’t the best way to go about that because it could interfere with the functioning of NK cells.

It will have an opportunity to gauge the reaction to that hypothesis when it presents updated data from the AML study at the American Society of Hematology (ASH) meeting in Atlanta next month.

“We remain convinced, based on broad preclinical evidence, that NK cells play an important role in cancer immunosurveillance,” said Innate’s CEO Mondher Mahjoubi.

“Together with [BMS] we will further examine these data to better understand the results and explore whether other combinations should be investigated.”

If Innate and BMS can’t see a way to advance lirilumab, Innate will have to turn its attention to monalizumab, a CD94/NKG2A-targeting immuno-oncology candidate heading for mid-stage testing as a monotherapy and in combination with AstraZeneca’s PD-L1 inhibitor Imfinzi (durvalumab) in a range of solid tumors and blood cancers, and anti-KIR3DL2 IPH4102 for lymphomas in phase 1.

Suggested Articles

The FDA has cleared its first duodenoscope designed to make the intricate, moving and difficult-to-clean parts in the head of the device disposable.

As Relay looks to enter the clinic in 2020, the company is adding a trio of biopharma vets to its leadership team.

A phase 3 trial of Myovant Sciences’ relugolix in prostate cancer has met its primary endpoint, teeing the company up to file for FDA approval.